» » »

Treatment for Ewing's Sarcoma Boston MA

Preliminary research suggests that the anticancer drug figitumumab might be an effective treatment for Ewing's sarcoma, a cancer that affects the areas in and near the bone, mainly in teenage boys.

Therese M Mulvey, MD
(617) 479-3550
10 Willard St
Quincy, MA
Business
Commonwealth Physicians Services Inc
Specialties
Oncology

Data Provided by:
Aileen B Chen
(617) 726-8650
55 Fruit St
Boston, MA
Specialty
Radiation Oncology

Data Provided by:
Noah C Choi, MD
(617) 726-6050
55 Fruit St
Boston, MA
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Kenneth Kenji Tanabe
(617) 724-3868
55 Fruit St
Boston, MA
Specialty
General Surgery, Surgical Oncology

Data Provided by:
Osei-Tutu Owusu, MD
(781) 363-6161
1 Boston Medical Ctr Pl
Boston, MA
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Science And Tech, Sch Of Med, Kumasi, Ghana
Graduation Year: 1984

Data Provided by:
Allan Kliman
(617) 573-2618
125 Nashua St
Boston, MA
Specialty
Internal Medicine, Hematology / Oncology

Data Provided by:
Torunn Yock
(617) 724-1548
100 Blossom St
Boston, MA
Specialty
Radiation Oncology

Data Provided by:
Katayoon Goodarzi
(617) 636-5000
750 Washington St
Boston, MA
Specialty
Hematology

Data Provided by:
Dr.Jason Efstathiou
(617) 726-1160
55 Fruit St
Boston, MA
Gender
M
Speciality
Oncologist
General Information
Accepting New Patients: Yes
RateMD Rating
3.0, out of 5 based on 1, reviews.

Data Provided by:
Robert Paul Hasserjian
(617) 724-1445
55 Fruit St
Boston, MA
Specialty
Hematology

Data Provided by:
Data Provided by:

Treatment for Ewing's Sarcoma

Provided By:

WEDNESDAY, Dec. 23 (HealthDay News) -- Preliminary research suggests that the anticancer drug figitumumab might be an effective treatment for Ewing's sarcoma, a cancer that affects the areas in and near the bone, mainly in teenage boys.

The drug must undergo two more phases of testing, however, according to a report published in the Dec. 23 online edition of The Lancet Oncology.

In the first phase of research, scientists looked at 29 patients with advanced sarcomas who received the drug between 2006 and 2008. The researchers wanted to assess its safety and ability to be tolerated.

Patients did experience some side effects, such as deep venous thrombosis, back pain and vomiting. Some of the patients appeared to respond well to the drug, the study authors noted.

"Figitumumab is well-tolerated and has antitumor activity in Ewing's sarcoma, warranting further investigation in this disease," the researchers wrote. "Our results show that figitumumab can be safe for both adult and pediatric sarcoma patients, and has single-agent antitumor activity in different sarcoma subtypes, including Ewing's sarcoma."

In a commentary accompanying the study, doctors wrote that "five-drug chemotherapy is routine in the treatment of Ewing's sarcoma, therefore improvement in outcome for these patients will likely require demonstration of the feasibility of combining the antibody with standard chemotherapy."

More information

The U.S. National Library of Medicine has more on Ewing's sarcoma.

SOURCE: The Lancet Oncology, news release, Dec. 23, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com